Off-label use as a standard of care

In the October issue of the Journal, Brown et al report that three intravitreal VEGF-I ’s (vascular endothelial growth factor inhibitors), ranibizumab, aflibercept and bevacizumab, were cost-effective for the treatment of NVAMD (neovascular age-related macular degeneration). Further, they found that bevacizumab was several-fold more cost-effective than ranibizumab and aflibercept.1 While neither of us are pharmaco-epidemiologists, the methods used by this experienced group of researchers appear to be valid.

Source: American Journal of Ophthalmology - October 14, 2020 Category: Opthalmology Authors: Gary D. Novack, Ala Moshiri Tags: Editorial Source Type: research